Extraocular Blood Flow and Endothelin-1 Plasma Levels in Patients with Multiple SclerosisPache M.a · Kaiser H.J.a · Akhalbedashvili N.b · Lienert C.b · Dubler B.a · Kappos L.b · Flammer J.a
aUniversity Eye Clinic Basel and bDepartment of Neurology, University Hospital Basel, Basel, Switzerland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
In order to evaluate whether plasma levels of the potent vasoconstrictor endothelin-1 (ET-1) are increased in patients with multiple sclerosis (MS) and whether these patients exhibit an ET-1-mediated vascular dysregulation, ET-1 plasma levels were measured in 30 patients with MS. Blood flow velocities in the ophthalmic artery, central retinal artery, central retinal vein, short lateral posterior ciliary artery, and short medial posterior ciliary artery were assessed in parallel. ET-1 plasma levels were significantly increased in MS patients when compared to sex- and age-matched healthy controls (2.0 ± 0.4 pg/ml, range 1.1–2.8 vs. 1.5 ± 0.2 pg/ml, range 0.9–2.0; p < 0.001). Moreover, the patients exhibited significant alterations of extraocular blood flow. The role of ET-1 in the inflammatory process remains to be clarified.
© 2003 S. Karger AG, Basel
- Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med 2000;343:938–952.
James PB: Multiple sclerosis or blood-brain barrier disease. Lancet 1989;i:46.
- Flachenecker P, Wolf A, Krauser M, Hartung HP, Reiners K: Cardiovascular autonomic dysfunction in multiple sclerosis: Correlation with orthostatic intolerance. J Neurol 1999;246:578–586.
- Acevedo AR, Nava C, Arriada N, Violante A, Corona T: Cardiovascular dysfunction in multiple sclerosis. Acta Neurol Scand 2000;101:85–88.
Speciale L, Sarasella M, Ruzzante S, Caputo D, Mancuso R, Calvo MG, Guerini FR, Ferrante P: Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol 2000;6(suppl 2):S62–S66.
Ripodas A, de Juan JA, Roldan-Pallares M, Bernal R, Moya J, Chao M, Lopez A, Fernandez-Cruz A, Fernandez-Durango R: Localisation of endothelin-1 mRNA expression and immunoreactivity in the retina and optic nerve from human and porcine eye. Evidence for endothelin-1 expression in astrocytes. Brain Res 2001;912:137–143.
- Cardell LO, Uddman R, Edvinsson L: Endothelins: A role in cerebrovascular disease? Cephalalgia 1994;14:259–265.
- Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, Nunez DJ, Capper SJ, Brown MJ: A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Colch) 1990;78:261–264.
Morise T, Takeuchi Y, Takeda R, Karayalcin U, Yachie A, Miyawaki T: Increased plasma endothelin levels in Kawasaki disease: A possible marker for Kawasaki disease. Angiology 1993;44:719–723.
- Gallai V, Sarchielli P, Firenze C, Trequattrini A, Paciaroni M, Usai F, Palumbo R: Endothelin-1 in migraine and tension-type headache. Acta Neurol Scand 1994;89:47–55.
Haq A, El-Ramahi K, Al-Dalaan A, Al-Sedairy ST: Serum and synovial fluid concentrations of endothelin-1 in patients with rheumatoid arthritis. J Med 1999;30:51–60.
Pache M, Kaiser HJ, Haufschild T, Lubeck P, Flammer J: Increased endothelin-1 plasma levels in giant cell arteritis: A report on four patients. Am J Ophthalmol 2002;133:160–162.
- Haufschild T, Shaw SG, Kesselring J, Flammer J: Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol 2001;21:37–38.
- Haefliger IO, Flammer J, Luscher TF: Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci 1992;33:2340–2343.
- Schmetterer L, Findl O, Strenn K, Jilma B, Graselli U, Eichler HG, Wolzt M: Effects of endothelin-1 (ET-1) on ocular hemodynamics. Curr Eye Res 1997;16:687–692.
- Dallinger S, Dorner GT, Wenzel R, Graselli U, Findl O, Eichler HG, Wolzt M, Schmetterer L: Endothelin-1 contributes to hyperoxia-induced vasoconstriction in the human retina. Invest Ophthalmol Vis Sci 2000;41:864–869.
- Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
- Moreau P, Takase H, Kung CF, Shaw S, Luscher TF: Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension 1997;29:763–769.
- Kaiser HJ, Schotzau A, Flammer J: Blood-flow velocities in the extraocular vessels in normal volunteers. Am J Ophthalmol 1996;122:364–370.
- Kaiser HJ, Schoetzau A, Stumpfig D, Flammer J: Blood-flow velocities of the extraocular vessels in patients with high-tension and normal-tension primary open-angle glaucoma. Am J Ophthalmol 1997;123:320–327.
Flammer J, Pache M, Resink T: Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001;20:319–349.
- Simonson MS, Dunn MJ: Cellular signaling by peptides of endothelin gene family. FASEB J 1990;4:2989–3000.
MacLean MR, McGrath JC: Effects of pre-contraction with endothelin-1 on alpha 2-adrenoceptor- and (endothelium-dependent) neuropeptide Y-mediated contractions in the isolated vascular bed of the rat tail. Br J Pharmacol 1990;101:205–211.
- Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997–1001.
- Nakayama K, Ishigai Y, Uchida H, Tanaka Y: Potentiation by endothelin-1 of 5-hydroxytryptamine-induced contraction in coronary artery of the pig. Br J Pharmacol 1991;104:978–986.
- Meyer P, Flammer J, Luscher TF: Endothelium-dependent regulation of the ophthalmic microcirculation in the perfused porcine eye: Role of nitric oxide and endothelins. Invest Ophthalmol Vis Sci 1993;34:3614–3621.
- Haefliger IO, Flammer J, Luscher TF: Heterogeneity of endothelium-dependent regulation in ophthalmic and ciliary arteries. Invest Ophthalmol Vis Sci 1993;34:1722–1730.
Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM: Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998;31(suppl 1):S545–S547.
- Zouki C, Baron C, Fournier A, Filep JG: Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: Role of ET(A) receptors and platelet-activating factor. Br J Pharmacol 1999;127:969–979.
Fernandez-Patron C, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906–911.
- Leppert D, Lindberg RL, Kappos L, Leib SL: Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001;36:249–257.
- Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, Ward GA, Gearing AJ, Miller KM: Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 1997;74:85–94.
Graesser D, Mahooti S, Madri JA: Distinct roles for matrix metalloproteinase-2 and alpha4 integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis. J Neuroimmunol 2000;109:121–131.
- Meyer P, Lang MG, Flammer J, Luscher TF: Effects of calcium channel blockers on the response to endothelin-1, bradykinin and sodium nitroprusside in porcine ciliary arteries. Exp Eye Res 1995;60:505–510.
- Toriu N, Sasaoka M, Shimazawa M, Sugiyama T, Hara H: Effects of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits. J Ocul Pharmacol Ther 2001;17:131–149.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.